Search

Your search keyword '"Bonotto, Marta"' showing total 170 results

Search Constraints

Start Over You searched for: Author "Bonotto, Marta" Remove constraint Author: "Bonotto, Marta"
170 results on '"Bonotto, Marta"'

Search Results

2. First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study

3. Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget’s disease of the vulva

4. The SENECA study: Prognostic role of serum biomarkers in older patients with metastatic colorectal cancer

7. Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results

9. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis

10. Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis

14. Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS)

16. Multidisciplinary Team Meeting Proposal and Final Therapeutic Choice in Early Breast Cancer: Is There an Agreement?

17. Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation

18. Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation

19. Erratum to: Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group

21. Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer

22. Refining neutropenia risk assessment in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC) through a cell-free DNA workflow (cfDNA).

23. Liquid biopsy for baseline evaluation of tumor burden in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A proof of principle study.

24. Uncovering the differential impact of ESR1 and PIK3CA codon variants on the clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS).

25. Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer

26. Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer

27. Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study

28. Abstract P5-14-08: Predictors of relative dose intensity and early dose reduction in patients with metastatic breast cancer treated with palbociclib and endocrine therapy

29. Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker

30. Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study.

31. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients

32. Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.

33. Association of clinical factors and biological subtypes with different Ca15-3 levels in metastatic breast cancer.

34. Integration of lymphocyte ratios (LRs) and circulating tumor cells (CTCs) characterization: The interplay between immunity and metastatic breast cancer (MBC).

35. Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis

36. Preliminary results from CAMEO-PRO study: Complementary and alternative medicine in oncology—Physicians inform oncological patients.

37. Setting and timing of end-of-life care in cancer patients.

38. Determinants of adjuvant chemotherapy use in small luminal-like breast cancer.

39. Immunotherapy for colorectal cancer: where are we heading?

40. Immunotherapy for gastric cancers: emerging role and future perspectives

44. Molecular classifications of gastric cancers: Novel insights and possible future applications

45. The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients

46. The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients

47. Apatinib for gastric cancer: are we moving the antiangiogenic strategy any forward?

48. Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey.

49. Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials

Catalog

Books, media, physical & digital resources